TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must be diagnosed with PMF, PPV-MF or PET-MF according to the 2008 World Health Organization criteria~* Subjects with MF requiring therapy must be classified as high risk OR intermediate risk level 2 according to the prognostic factors defined by the International Working Group~* Subjects with an ECOG performance status of 0, 1, 2 or 3~* Subjects with peripheral blood blast count of \< 10%.~* Subjects who have not previously received treatment with a JAK inhibitor~Exclusion Criteria:~* Subjects with a life expectancy of less than 6 months~* Subjects with inadequate bone marrow reserve as demonstrated by specific clinical laboratory counts~* Subjects with any history of platelet counts \< 50,000/µL or ANC \< 500/µL except during treatment for a myeloproliferative disorder or treatment with cytotoxic therapy for any other reason~* Subjects with inadequate liver or renal function~* Subjects with clinically significant bacterial, fungal, parasitic or viral infection which require therapy~* Subjects with an active malignancy over the previous 5 years except specific skin cancers~* Subjects with severe cardiac conditions~* Subjects who have had splenic irradiation within 12 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ruxolitinib (Type: EXPERIMENTAL): 5 mg tablets administered orally in an outpatient setting according to the protocol-specified dosing schedule
- Best Available Therapy (BAT) (Type: ACTIVE_COMPARATOR): Commercially available therapy, oral or parenteral, per manufacturer's instructions and Investigator discretion. BAT included the option of no treatment.~Patients randomized to BAT were eligible to cross over to receive open-label ruxolitinib after a qualifying progression event, if they met the safety criteria. After the primary analysis in January 2011, patients randomized to receive BAT were allowed to cross over to receive ruxolitinib and move to the extension phase of the study without a qualifying progression event.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sutent and Radiation as Treatment for Limited Extent Metastatic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Zubrod Performance Scale 0-1~* Metastatic disease confirmed by biopsy or imaging~* 5 or fewer sites of metastatic disease on tumor staging (either CT chest/abdomen/pelvis plus bone scan or whole body FDG-PET)~* All tumors measure \< 6 cm~* Age \> 18~* Chemotherapy must be completed at least 2 weeks prior to radiation~* Signed informed consent~* Adequate bone marrow function, defined as follows;~  1. Platelets \> 100,000 cells/mm3 based upon CBC/differential obtained within 2 weeks prior to registration on study~ 2. Absolute neutrophil count (ANC) \> 1,800 cells/mm3 based on CBC/differential obtained within 2 weeks prior to registration on study~ 3. Hemoglobin \> 8.0 g/dl based upon CBC/differential obtained within 2 weeks prior to registration on study (Note: The use of transfusion or other intervention to achieve Hgb \> 8.0 g/dt is acceptable.)~Exclusion Criteria:~* Other coexisting malignancies or malignancies diagnosed within the previous 3 years with the exception of basal cell carcinoma, cervical carcinoma in situ, and other treated malignancies with no evidence of disease for at least 3 years~* Uncontrolled intercurrent illness including, but not limited to, ongoing active infection, symptomatic congestive heart failure (CHF), unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with the study requirements~* Patients with clinically significant pulmonary dysfunction, cardiomyopathy, or any history of clinically significant CHF are excluded. The exclusion of patients with active coronary heart disease will be at the discretion of the attending physician.~* Patients with exudative, bloody, or cytologically malignant effusions are not eligible.~* Pregnancy or breast feeding (Women of child-bearing potential are eligible, but must consent to using effective contraception during therapy and for at least 3 months after completing therapy)~* Patients must have no uncontrolled active infection other than that not curable without treatment of their cancer.~* Prior radiation to target area~* Patient may not be receiving any other investigational agents during radiotherapy.~* Prior history of non-inducible bleeding (12/16/09).~* Requirement for continuation of anticoagulation (defined as Coumadin, lovenox, heparin, plavix, aspirin, NSAIDs or similar drugs) during treatment (12/16/09)~* Under 18 years of age

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): Participants treated with chemotherapy and radiotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female Europeans aged 18 years or older with moderate to severe HTN, defined as follows (conventional BP measurements)~Exclusion Criteria:~* Female patients of childbearing potential pregnant, lactating or planning to become pregnant during the trial period.~* Patients with serious disorders which may limit the ability to evaluate the efficacy or safety of the study medication, including cerebrovascular, cardiovascular, renal, respiratory, hepatic, gastrointestinal, endocrine or metabolic, haematological or oncological, neurological and psychiatric diseases.~* Patients having a history of the following within the last six months:~  * myocardial infarction,~ * unstable angina pectoris,~ * percutaneous coronary intervention,~ * severe heart failure,~ * hypertensive encephalopathy, cerebrovascular accident (stroke) or~ * transient ischaemic attack.~* Patients with clinically significant abnormal laboratory values at screening.~* Patients with secondary HTN.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): olmesartan medoximil (OM)/ hydrochlorothiazide (HCTZ) 40/25 mg + OM/HCTZ 20/25 mg matching placebo
- 2 (Type: EXPERIMENTAL): olmesartan medoximil (OM)/ hydrochlorothiazide (HCTZ)20/25 mg + OM/HCTZ 40/25 matching placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Osteoarthritis of the knee or hip confirmed by X-ray~* Documented history that subject tried the following medications and had insufficient pain relief or is cannot take or tolerate them: acetaminophen, NSAIDs and either tramadol or opioids~* Meet the protocol requirements for pain at screening and pain, physical function and patient global assessment of osteoarthritis at baseline~* Willing to discontinue all pain medications except study medication and rescue medication during the course of the study and use those as directed per protocol~* Women able to have children must agree to use 2 forms of contraception during the study~Exclusion Criteria:~* Body Mass Index (BMI) greater than 39~* History of diseases other than osteoarthritis in a shoulder, hip or knee (example, rheumatoid arthritis, gout, joint infections, osteonecrosis)~* Patients with x-ray showing joint conditions such as osteonecrosis (dead bone) or certain types of fractures~* Patients who have had significant trauma or surgery to a knee, hip or shoulder within the previous year~* Planned surgical procedure during the study~* Patients who are largely or wholly incapacitated (example bedridden or confined to a wheelchair, permitting little or no self-care)~* Patients who would be unwilling or unable to undergo joint replacement surgery if one eventually became necessary~* Patients with significant conditions other than osteoarthritis that could interfere with assessment of pain in the joints (example fibromyalgia, lupus erythematosus)~* Patients with significant heart, neurological or psychiatric diseases~* Patients who had cancer other than certain skin cancers within the past 5 years~* Patients with alcohol, analgesic (pain medications) or drug abuse within the past 2 years~* Women who are pregnant, breast-feeding or intending to become pregnant or breast-feed during the course of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): placebo administered subcutaneously at day 0 and week 8
- Tanezumab 2.5 mg (Type: EXPERIMENTAL): tanezumab 2.5 mg administered subcutaneously at day 0 and week 8
- Tanezumab 2.5mg/5mg (Type: EXPERIMENTAL): tanezumab 2.5 mg administered subcutaneously at day 0 and tanezumab 5 mg administered subcutaneously at week 8

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PT001 MDI Versus Atrovent Study in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Key Inclusion Criteria:~* Signed written informed consent~* 40 - 80 years of age~* Clinical history of COPD with airflow limitation that is not fully reversible~* Females of non-child bearing potential or females of child bearing potential with negative pregnancy test; and acceptable contraceptive methods~* Current/former smokers with at least a 10 pack-year history of cigarette smoking~* A measured post- bronchodilator FEV1/FVC ratio of \< or = 0.70~* A measured post- bronchodilator FEV1 \> or = 750ml or 30% predicted and \< or = 80% of predicted normal values~* Able to change COPD treatment as required by protocol~Key Exclusion Criteria:~* Women who are pregnant or lactating~* Primary diagnosis of asthma~* Alpha-1 antitrypsin deficiency as the cause of COPD~* Active pulmonary diseases~* Prior lung volume reduction surgery~* Abnormal chest X-ray (or CT scan) not due to the presence of COPD~* Hospitalized due to poorly controlled COPD within 3 months of Screening~* Clinically significant medical conditions that preclude participation in the study (e.g. clinically significant abnormal ECG, uncontrolled hypertension, glaucoma, symptomatic prostatic hypertrophy)~* Cancer that has not been in complete remission for at least 5 years~* Treatment with investigational study drug or participation in another clinical trial or study within the last 30 days or 5 half lives~Other inclusion/exclusion criteria as defined in the protocol

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- PT001 MDI (Dose 1) (Type: EXPERIMENTAL): PT001 MDI
- PT001 MDI (Dose 2) (Type: EXPERIMENTAL): PT001 MDI
- PT001 MDI (Dose 3) (Type: EXPERIMENTAL): PT001 MDI
- PT001 MDI (Dose 4) (Type: EXPERIMENTAL): PT001 MDI
- Ipratropium Bromide HFA Inhalation Aerosol (Type: ACTIVE_COMPARATOR): Ipratropium Bromide HFA Inhalation Aerosol
- Placebo MDI (Type: PLACEBO_COMPARATOR): PT001 Placebo MDI

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Feasibility of Florbetapir Quantitation in Europe

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Readers have undergone Amyvid reader training~* Readers have not more than minimal experience with quantitation of amyloid PET scans~Exclusion Criteria:~* Readers have previously been trained to quantitate amyloid PET scans

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Physician Readers (Type: EXPERIMENTAL): Physician readers will interpret Amyvid scans using qualitative analysis followed by the use of quantitation. No subjects will be exposed to Florbetapir(18F) as part of this study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: OCS-01 in Treating Inflammation and Pain in Post-cataract Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Provide written informed consent, approved by the appropriate ethics committee;~2. Be able to comply with the study requirements and visit schedule;~3. Be at least 18 years of age of either sex or any race;~4. Be planning to undergo unilateral cataract extraction via phacoemulsification and PCIOL implantation in the study eye;~5. Have an anterior chamber cell score ≥ 2 at Visit 2 (Day 1 \[18 to 30 hours post-uncomplicated cataract surgery without vitreous loss\]);~6. Have a pin-hole visual acuity (VA) without any other correction \> 20 letters (approximately 20/400) in the operative eye and \> 35 letters (approximately 20/200) in the fellow eye as measured using an Early Treatment for Diabetic Retinopathy Study (ETDRS) chart at Visit 1 (Day -1 to Day -28 \[prior to surgery\]);~7. Have a negative urine pregnancy test at Visit 1 (Day -1 to Day -28 \[prior to surgery\]),~Exclusion Criteria:~1. Have a known sensitivity or allergy to dexamethasone, corticosteroids, or any of the study medication's components;~2. Be monocular;~3. Have any intraocular inflammation (e.g. white blood cells or flare) present in either eye at the Visit 1 (Day -1 to Day -28 \[prior to surgery\]) slit lamp examination;~4. Have a score \> 0 on the Ocular Pain Assessment at Visit 1 (Day -1 to Day -28 \[prior to surgery\]) in the study eye;~5. Use anti-inflammatory agents, analgesics/pain relievers (including opioids, narcotics, and other pain medications), or immunomodulating agents, systemically or in either eye, and/or use medications for benign prostatic hyperplasia (BPH), from the washout period through the duration of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OCS-01 1.5% mg/mL QD (Type: EXPERIMENTAL): eye drops
- OCS-01 1.5% mg/mL BID (Type: EXPERIMENTAL): eye drops
- Placebo (Vehicle) BID (Type: PLACEBO_COMPARATOR): eye drops

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2b Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing unilateral total knee arthroplasty~Exclusion Criteria:~* risks of hemorrhage~* thromboembolic risks~* weight less than 40 kg~* pregnant, suspect pregnancy, or subjects who want to become pregnant

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 84 Years
- Healthy Volunteers: f

Study Arms:
- DU-176b 5 mg (Type: EXPERIMENTAL): None
- DU-176b 15 mg (Type: EXPERIMENTAL): None
- DU-176b 30 mg (Type: EXPERIMENTAL): None
- DU-176b 60 mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Infliximab (Remicade) in Patients With Ankylosing Spondylitis.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Have had a diagnosis of definite Akylosing Spondylitis for at least 3 months prior to screening~* Have active disease with spinal pain~* receiving or intolerant to standard anti-inflammatory agents~Exclusion Criteria:~* Have Rheumatoid Arthritis, systemic lupus erythematosus, or other inflammatory rheumatic disease~* Have a documented history of fibromyalgia~* Have total ankylosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Post Marketing Observational Study (PMOS) to Assess Quality of Life in Swedish Hidradenitis Suppurativa (HS) Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Hidradenitis Suppurativa~* Prescribed Adalimumab according to the Summary of Product Characteristics (SmPC)~* Willingness to sign and date a Patient Information/Informed Consent Form~Exclusion Criteria:~* Prior biologic treatment discontinued \<6 months before the baseline visit~* Patient not able to understand the language of the provided patient questionnaires~* History of non-compliance with medication or a medical history that could enhance non-compliance with medication, as determined by the investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Patients with Hidradenitis Suppurativa (Type: None): Patients with moderate or severe HS treated prescribed adalimumab according to the Swedish Summary of Product Characteristics and treated as per routine clinical practice.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: RN624 In Adult Patients With Chronic Low Back Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female of any race, \>18 years of age and have BMI ≤39 kg/m2~* Present with duration of chronic low back pain of ≥3 months requiring regular use of analgesic medication (\>4 days per week for the past month)~* Primary location of low back pain is between the 12th thoracic vertebra and the lower gluteal folds, with or without radiation into the posterior thigh, classified as Category 1 or 2 according to the classification of the Quebec Task Force in Spinal Disorders~* Must have a score of ≥4 for Low Back Pain Intensity (NRS) while on current treatment at Screening, and completes at least 4 daily pain diaries during the 5 days prior to Randomization, with an average Low Back Pain Intensity (NRS) score of ≥4~Exclusion Criteria:~* Back pain due to visceral disorder (i.e. endometriosis) or Back pain due to recent major trauma (i.e. vertebral fracture, post-traumatic spondylolisthesis)~* History of lumbosacral radiculopathy, spinal stenosis associated with neurological impairment, or neurogenic claudication~* Osteoporotic compression fracture within the last 6 months~* Known history of: Rheumatoid arthritis; Seronegative spondyloarthropathy (i.e., ankylosing spondylitis, psoriatic arthritis, reactive arthritis, inflammatory bowel disease-related arthropathy); Paget's disease of spine, pelvis or femur; Fibromyalgia; Tumors or infections of the spinal cord~* Patients receiving acetaminophen only to manage their chronic low back pain~* Any uncontrolled or untreated chronic disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Naproxen (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None
- RN624 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety/Efficacy Study of Oxycodone HCl/Niacin to Treat Pain After Bunionectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is male or female at least 18 years of age~* For women of child-bearing potential: woman who is not pregnant and not nursing, and who is practicing an acceptable method of birth control~* Patient is scheduled to have a bunionectomy~* Patient must be willing to stay at the study site for at least 48 hours from the initial dose of study medication post-surgery~Exclusion Criteria:~* Patient has a current disease or history of a disease that will impact the study or the patient's well-being~* Patient has used or intends to use any of the medications that are prohibited by the protocol~* Patient has a history of drug or alcohol abuse or dependence, or patient has a positive urine drug screen~* Patient is hypersensitive to any of the medications to be used in the study~* Patient has taken another investigational drug within 30 days prior to Screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Tablet
- Acurox 5/30mg (Type: ACTIVE_COMPARATOR): Oxycodone HCl 5mg/Niacin 30mg tablet
- Acurox 7.5/30 (Type: PLACEBO_COMPARATOR): Oxycodone HCl 7.5mg/Niacin 30mg tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete